secwatch.observer — SEC 8-K summary
======================================

Issuer:     BOSTON SCIENTIFIC CORP (BSX)
CIK:        0000885725
Form:       8-K
Filed at:   2025-05-28T23:59:59+00:00
Accession:  0000885725-25-000033
Event type: other_material
Sentiment:  negative
Materiality: 0.75
Item codes: 8.01
LLM model:  deepseek-v4-flash:cloud@v2

Boston Scientific discontinues ACURATE aortic valve systems globally; maintains adjusted EPS guidance
--------------------------------------------------------------------------------

- Discontinuing worldwide sales of ACURATE neo2 and ACURATE Prime Aortic Valve Systems; no longer pursuing U.S. FDA or other approvals.
- Decision driven by increased regulatory requirements and prohibitive additional investments needed to maintain or obtain approvals.
- Still expects to achieve Q2 and full year 2025 reported and organic sales and adjusted EPS guidance issued on April 23.
- Not reaffirming Q2 and full year 2025 GAAP EPS guidance at this time; more details on Q2 2025 earnings call.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/885725/000088572525000033/0000885725-25-000033-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/885725/000088572525000033/bsx-20250528.htm
  HTML page:      https://secwatch.observer/filing/0000885725-25-000033

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer